Steven Shak

41.1k citations

133 papers · 28.1k indexed · 9 hit papers · h-index 54

Impact in

Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis

Papers in

Cancer Research 78
- Breast Cancer Treatment Studies 74
- Cancer Genomics and Diagnostics 20
Oncology 56
- HER2/EGFR in Cancer Research 33
- Cancer Treatment and Pharmacology 16

Co-authors: Dennis J. Slamon Virginia Paton Janet Wolter W. Eiermann Larry Norton Alex Bajamonde José Baselga Mark D. Pegram
Journals: Journal of Clinical Oncology (54 papers)Cancer Research (14 papers)Breast Cancer Research and Treatment (7 papers)Clinical Cancer Research (4 papers)European Journal of Cancer (4 papers)
Partner nations: United States Germany Canada

In The Last Decade

Steven Shak

133 papers receiving 27.3k citations

Hit Papers

9 papers align trajectories log scale

A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling 2014 · 447 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 European Urology
2010 Journal of Clinical Oncology
2006 Journal of Clinical Oncology
2004 New England Journal of Medicine
2002 Journal of Clinical Oncology
2002 Journal of Clinical Oncology
2001 New England Journal of Medicine
1999 Journal of Clinical Oncology
1990 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Steven Shak

Since Specialization

Citations

This map shows the geographic impact of Steven Shak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Shak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Shak more than expected).

Fields of papers citing papers by Steven Shak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Shak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Shak. The network helps show where Steven Shak may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Steven Shak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Shak Line = papers co-authored together Steven Shak links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Journal of Clinical Oncology ·Kevin Kalinsky, William E. Barlow, Harsh B. Pathak, Julie R. Gralow, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen Chia, Priya Rastogi, Anne F. Schott, Steven Shak, Rawashdeh, Gabriel N. Hortobágyi, Funda Meric‐Bernstam, Priyanka Sharma, Lajos Pusztai, Alastair M. Thompson, Andrew K. Godwin	2024	5
2	Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer Journal of Clinical Oncology ·Lajos Pusztai, Erekpitan Omoikhefe Ola-Adisa, Kathy S. Albain, William E. Barlow, Salomon M. Stemmer, Allison Meisner, Gabriel N. Hortobágyi, Steven Shak, James M. Rae, Frederick L. Baehner, Priyanka Sharma, Kevin Kalinsky	2024	1
3	Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial Journal of Clinical Oncology ·Corey Speers, W. Fraser Symmans, William E. Barlow, Yves Gasse, Stephanie The, Lili Du, James M. Rae, Steven Shak, Yanina Keil, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobágyi, Daniel F. Hayes, Kathy S. Albain, Andrew K. Godwin, Alastair Thompson	2023	9
4	Molecular Characterization and Mortality From Breast Cancer in Men Journal of Clinical Oncology ·Suleiman Massarweh, George W. Sledge, Dave P. Miller, Philip Whitmore, Valentina I. Petkov, Steven Shak	2018	54
5	Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database Breast Cancer Research and Treatment ·Megan C. Roberts, Dave P. Miller, Steven Shak, Valentina I. Petkov	2017	77
6	First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result Annals of Oncology ·Salomon M. Stemmer, Davide Bellassai, Shulamit Rizel, Masomeh Kamakoli, Clara María Temporelli, Tamar Peretz, Lior Soussan‐Gutman, Avital Bareket‐Samish, Kim L. Isaacs, Ora Rosengarten, Georgeta Fried, Cecilia Svedman, Steven Shak, Nicky Liebermann, Noa Ben-Baruch	2016	3
7	Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC) Annals of Oncology ·Steven Shak, Dave P. Miller, Nadia Howlader, Henry H.W. Shih, Lucas Morgan Disalvo, Nicola Schussler, Kathleen A. Cronin, James H. Oliver, Lynne Penberthy, Valentina I. Petkov	2016	8
8	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 Breast Cancer Research ·Edith A. Perez, Frederick L. Baehner, Steven M. Butler, E. Aubrey Thompson, Amylou C. Dueck, Farid Jamshidian, Diana B. Cherbavaz, Carl Yoshizawa, Steven Shak, Peter A. Kaufman, Nancy E. Davidson, Julie R. Gralow, Yan W. Asmann, Karla V. Ballman	2015	17
9	Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581 Journal of Clinical Oncology ·Alan P. Venook, Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy L. Frankel, Kim M. Clark-Langone, Carl Millward, Steven Shak, Richard M. Goldberg, Najjia N. Mahmoud, Robert S. Warren, Richard L. Schilsky, Monica M. Bertagnolli	2013	117
10	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study Breast Cancer Research and Treatment ·Lawrence J. Solin, Robert P. Gray, Lori J. Goldstein, Abram Recht, Frederick L. Baehner, Steven Shak, Sunil Badve, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano	2012	59
11	Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Clinical Cancer Research ·Joseph A. Sparano, Lori J. Goldstein, Barrett H. Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L. Baehner, Roberto Bugarini, Jae-Yoon Jeon, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, Paraic A. Kenny, George W. Sledge, Nem Raj Sunda	2011	20
12	Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin Journal of Clinical Oncology ·Michael J. O’Connell, Ian C. Lavery, Greg Yothers, Soonmyung Paik, Kim M. Clark-Langone, Margarita Lopatin, Drew Watson, Frederick L. Baehner, Steven Shak, Joffre Baker, J. Wayne Cowens, Norman Wolmark	2010	220
13	Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study Journal of Clinical Pathology ·Suzanne Drury, Janine Salter, Frederick L. Baehner, Steven Shak, Mitch Dowsett	2010	21
14	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Clinical Cancer Research ·Joseph A. Sparano, Lori J. Goldstein, Barrett H. Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L. Baehner, Roberto Bugarini, Laurentia Irina Tanase, Edith Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Robert P. Gray	2009	21
15	Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 Breast Cancer Research and Treatment ·Seung Sam Paik, Steven Shak, Gong Tang, par A. Kastler, Julie Baker, Michael Cronin, Yanina Keil, M M Walker, 阎汝辉, B Xiu, Jennifer Bryant, Norman Wolmark	2003	47
16	Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology ·Charles L. Vogel, Melody Cobleigh, Debu Tripathy, John Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael F. Press Hit paper breakdown →	2002	1508
17	First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer Oncology ·Charles L. Vogel, Melody Cobleigh, Debu Tripathy, John Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, K Thompson William, William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart	2001	145
18	Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus Journal of Clinical Investigation ·Ben‐Gary Harvey, Philip L. Leopold, Neil R. Hackett, А В Кухто, P. Mickey Williams, Washburne D. Shipton, Robert J. Kaner, Barbara Ferris, Igor Gonda, Theresa D. Sweeney, Ramachandran Ramalingam, Imre Kovesdi, Steven Shak, Ronald G. Crystal	1999	182
19	Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus European Respiratory Journal ·JM Zahm, И.В. Серых, Hassan Ali Abbasi, KB Madsen, A. Dabadie, Jesús Manuel Cuevas-Rincón, M. Roussey, Steven Shak, Édith Puchelle	1995	58
20	A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis New England Journal of Medicine ·Richard C. Hubbard, Noel G. McElvaney, P. Birrer, Steven Shak, Timothy Dolch, 鄭哲源, Margaret Wu, Milica S. Chernick, Ronald G. Crystal	1992	158

About Steven Shak

Steven Shak is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 133 papers that have together received 28.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (74 papers), HER2/EGFR in Cancer Research (33 papers), Advanced Breast Cancer Therapies (28 papers), Cancer Genomics and Diagnostics (20 papers), Cancer Treatment and Pharmacology (16 papers), Breast Lesions and Carcinomas (14 papers), Molecular Biology Techniques and Applications (12 papers) and Cystic Fibrosis Research Advances (11 papers). The work is most often cited by research in Cancer Research (11.2k citations), Oncology (16.7k citations), Radiology, Nuclear Medicine and Imaging (6.0k citations), Pathology and Forensic Medicine (3.3k citations) and Pulmonary and Respiratory Medicine (5.6k citations). Steven Shak has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Dennis J. Slamon, Virginia Paton, Janet Wolter, W. Eiermann, Larry Norton, Alex Bajamonde, José Baselga, Mark D. Pegram, Thomas Fleming and Brian Leyland‐Jones. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact